Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHISTA: Atezolizumab + Bevacizumab in Unresectable Hepatocellular Carcinoma
2020-001973-66Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Primary endpoint: Incidence of Grade 3-5 bleeding/haemorrhage. Started Jun 2021; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-001973-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001973-66.